30th week of 2012 patent applcation highlights part 47 |
Patent application number | Title | Published |
20120190591 | Assay Plates, Reader Systems and Methods for Luminescence Test Measurements - Luminescence test measurements are conducted using an assay module having integrated electrodes with a reader apparatus adapted to receive assay modules, induce luminescence, preferably electrode induced luminescence, in the wells or assay regions of the assay modules and measure the induced luminescence. | 2012-07-26 |
20120190592 | METHOD AND SYSTEM FOR REMOVING ORGANIC DEPOSITS - A method and a thermo-chemical system for removing organic deposits such as wax, asphaltenes and resins in oil well borehole, and oil production and transportation tubing and pathway. | 2012-07-26 |
20120190593 | PERMEABILITY BLOCKING WITH STIMULI-RESPONSIVE MICROCOMPOSITES - Disclosed is a two-component fluid loss control system comprising a core substrate and a polymeric shell cooperating with each other to form a microcomposite, wherein the core substrate and the polymeric shell are formed from different materials. The system can demonstrate switchable behavior. The core substrate and the polymeric shell can be further modified, where modifications cooperate with each other to form the microcomposite. Also disclosed are formulations for fluid loss control and methods for controlling fluid loss in a well. | 2012-07-26 |
20120190594 | Organoclay Materials for Environmentally Sensitive Regions - Fluids comprising oil; and an organophilic clay comprising a smectite clay modified by reaction with a protonated amphoteric surfactant. The smectite clay may be montmorillonite, beidellite, nontronite, or a combination thereof. The protonated amphoteric surfactant may be cetyl/myristyl amine oxide, a stearyl amine oxide, a stearyl betaine, or a combination thereof. In some cases, the fluid may also include water and/or a solid reactive metal. | 2012-07-26 |
20120190595 | Carboxylic Acid and Oxidizer Clean-Up Compositions and Associated Methods of Use in Subterranean Applications - Methods of reducing the viscosity of a viscosified treatment fluid; providing a clean-up composition comprising a carboxylic acid; a chlorite-based breaker system comprising an alkali metal compound and an activator wherein the activator comprises a metal and an amine. Placing a viscosified treatment fluid in a subterranean formation via a well bore penetrating the subterranean formation; first contacting the viscosified treatment fluid with the chlorite-based breaker; and then contacting the viscosified treatment fluid with the clean-up composition; and, allowing the viscosity of the viscosified treatment fluid to reduce. | 2012-07-26 |
20120190596 | Mutual Solvent-Soluble and/or Alcohol Blends-Soluble Particles for Viscoelastic Surfactant Fluids - Solid, particulate dicarboxylic acids may be fluid loss control agents and/or viscosifying agents for viscoelastic surfactant (VES) fluids in treatments such as well completion or stimulation in hydrocarbon recovery operations. The fluid loss control agents may include, but not be limited to, dodecanedioic acid, undecanedioic acid, decanedioic acid, azelaic acid, suberic acid, and mixtures thereof having a mesh size of from about 20 mesh to about 400 mesh (about 841 to about 38 microns). A mutual solvent or a blend of at least two alcohols subsequently added to the aqueous viscoelastic surfactant treating fluid will at least partially dissolve the solid, particulate dicarboxylic acid fluid loss control agents, and optionally also “break” or reduce the viscosity of the aqueous viscoelastic surfactant treating fluid. | 2012-07-26 |
20120190597 | Extrusion Process For Proppant Production - An extrusion method and apparatus are described for producing ceramics, glass, glass-ceramics, or composites suitable for use as proppants. The method includes forming one or more green body materials, extruding the green body materials to form a green body extrudate, separating and shaping the green body extrudate into individual green bodies, and sintering the green bodies to form proppants. The apparatus includes a means for forming an intimate mixture of green body materials, means to produce a green body extrudate, means for separating and shaping the green body extrudate into individual green bodies, and means to sinter the green green bodies to form proppants. | 2012-07-26 |
20120190598 | METALLIC NANOPARTICLE BIOCIDE IN INDUSTRIAL APPLICATIONS - A method includes providing and adding a measured dose amount of manufactured metallic nanoparticle material to a carrier material for pre-treatment of the carrier material prior to use of the carrier material and the manufactured metallic nanoparticle material in the sub-surface earth activity. Another method includes accessing a sub-surface earth opening used with a sub-surface earth activity, introducing an amount of manufactured metallic nanoparticle material into the sub-surface earth opening, and treating a sub-surface earth condition present at a sub-surface earth location accessible via the sub-surface earth opening. The sub-surface earth condition is treated with the manufactured metallic nanoparticle material. Another method includes accessing a product from a sub-surface earth location that is extracted in conjunction with the sub-surface earth activity, measuring and introducing a dose amount of manufactured metallic nanoparticle material with the product from the sub-surface earth location. | 2012-07-26 |
20120190599 | AQUEOUS COMPOSITIONS USEFUL IN FILLING AND CONVEYING OF BEVERAGE BOTTLES WHEREIN THE COMPOSITIONS COMPRISE HARDNESS IONS AND HAVE IMPROVED COMPATIBILITY WITH PET - The passage of a container along a conveyor is facilitated by applying to the container or conveyor aqueous compositions containing hardness ions. The compatibility of the aqueous compositions with PET bottles is improved when the ratio of hardness as CaCO | 2012-07-26 |
20120190600 | ENVIRONMENTALLY-FRIENDLY KELP-BASED ENERGY SAVING LUBRICANTS, BIOFUELS, AND OTHER INDUSTRIAL PRODUCTS - A natural algae-based synthetic lubricant derived from harvesting kelp from the ocean, recovering sieve sap from the kelp, drying the sieve sap, and removing salts and oxides to leave a composition having a concentration of polyols (Mannitol about 70% and Mannose about 0.4%) and about 28% by weight of a high molecular weight polymer. The synthetic lubricant may be used as a drag reducing agent and additive for existing lubricants and also further reacted with fatty esters to form a hybrid lubricant that may serve as a total replacement for existing lubricants. | 2012-07-26 |
20120190601 | VISCOSITY MODIFIER FOR LUBRICATING OILS, ADDITIVE COMPOSITION FOR LUBRICATING OILS, AND LUBRICATING OIL COMPOSITION - It is an object to provide a lubricating oil composition having low-temperature properties and fuel efficiency at high temperatures which are superior to those of conventional lubricating oil compositions, and to provide a viscosity modifier for lubricating oils and an additive composition for lubricating oils which are used for obtaining said composition. The viscosity modifier for lubricating oils of the present invention comprises a propylene copolymer (A) which has a density of 875 kg/m3 or less and which comprises 60 mole % or more of structural unit derived from propylene. | 2012-07-26 |
20120190602 | LUBRICATING GREASE COMPOSITIONS - Use of a lubricating grease composition in a mass flywheel application wherein the lubricating grease composition comprises: (i) a base oil having a density in the range of from 800 to 1000 Kg/m | 2012-07-26 |
20120190603 | ETHER COMPOUND, LUBRICANT CONTAINING SAME, AND COMPOSITION FOR LUBRICANT CONTAINING SAME - To provide an ether compound which is capable of maintaining high adhesion to a base material even in the presence of moisture, and a lubricant and a composition for a lubricant, containing the ether compound. | 2012-07-26 |
20120190604 | AZEOTROPIC COMPOSITIONS COMPRISING FLUORINATED OLEFINS FOR CLEANING APPLICATIONS - The present invention relates to azeotropic or azeotrope-like compositions comprising a fluorinated olefin having the formula E- or Z—C | 2012-07-26 |
20120190605 | USE OF TALLOW FATTY ALCOHOL ETHOXYLATES IN MACHINE DISHWASHING - The invention relates to nonionic surfactants of ethoxylates of linear C | 2012-07-26 |
20120190606 | MANUFACTURING METHOD OF A GLASS SUBSTRATE FOR A MAGNETIC DISK - An object of the invention is to remove effectively metallic contaminants adhering to the glass substrate surfaces without increasing roughness of the glass substrate surfaces in the glass substrate for a magnetic disk. In a manufacturing method of a glass substrate for a magnetic disk having a cleaning step of the glass substrate, the cleaning step comprising a cleaning treatment of contacting the glass substrate with an alkaline aqueous solution having a gluconate in concentration of not less than 0.05 wt % and not more than 2 wt % added thereto and a pH of not less than 9 and not more than 11 is appended. | 2012-07-26 |
20120190607 | DETERGENT COMPOSITION INCLUDING A SACCHARIDE OR SUGAR ALCOHOL - Solid detergent compositions according to the present invention include at least one alkali metal silicate, at least one polycarboxylic acid, at least one saccharide or sugar alcohol and water. Suitable saccharides include sucrose, fructose, inulin, maltose and lactulose, and may be present in the composition in a concentration of at least 0.5 wt %. Compositions according to certain embodiments form stable solid block detergent compositions that do not swell significantly even when subjected to elevated temperatures. | 2012-07-26 |
20120190608 | COATED CRYSTALLINE POLYCARBOXYLATE PARTICLES - A particulate material comprising a crystalline polycarboxylate wherein the particles of the material have a coating. A solid detergent composition comprising a crystalline polycarboxylate containing particulate material of the invention is also provided. The particulate material of the invention exhibits good building/chelancy properties and is especially suitable for use in detergent tablets. | 2012-07-26 |
20120190609 | METHOD FOR PRODUCING A LIPID PARTICLE, THE LIPID PARTICLE ITSELF AND ITS USE - A method for producing a lipid particle comprising the following: i) providing a first solution comprising denatured apolipoprotein, ii) adding the first solution to a second solution comprising at least two lipids and a detergent but no apolipoprotein, and iii) removing the detergent from the solution obtained in ii) and thereby producing a lipid particle. | 2012-07-26 |
20120190610 | TETRANECTIN-APOLIPOPROTEIN A-I, LIPID PARTICLES CONTAINING IT AND ITS USE - A lipid particle comprising an apolipoprotein, a phosphatidylcholine and a lipid, such as a phospholipid, fatty acid or steroid lipid. In one embodiment the lipid particle comprises only one apolipoprotein. In one embodiment the lipid particle is consisting of one apolipoprotein, a phospholipid, a lipid, and a detergent. In one embodiment the lipid is a second phosphatidylcholine, wherein the first phosphatidylcholine and the second phosphatidylcholine differ in one or two fatty acid residues or fatty acid residue derivatives which are esterified to the glycerol backbone of the phosphatidylcholine. In one embodiment the apolipoprotein is selected from an apolipoprotein that has the amino acid sequence selected from SEQ ID NO: 01, 02, 06, 66, and 67, or is a variant thereof that has at least 70% sequence identity with the selected sequence. | 2012-07-26 |
20120190611 | METHOD FOR TREATMENT OF INFLAMMATORY DISEASE AND DISORDER - The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators. Exemplary modulators include inhibitors of PKC-alpha, PKC-epsilon and PKC-eta, as well as activators of PKC-delta. | 2012-07-26 |
20120190612 | METHODS OF TREATMENT - The present invention relates to methods for inhibiting proliferation and/or migration of lymphatic endothelial cells and for inhibiting lymphangiogenesis, comprising administering to a subject, or to lymphatic endothelial cells derived therefrom, an effective amount of a collagen type IV-derived NC1 domain polypeptide or a fragment, derivative or variant thereof, a polynucleotide encoding the same, or an agent capable of increasing the expression or production of the NC1 domain polypeptide. Aso provided are methods for the treatment or prevention of diseases and conditions associated with aberrant lymphatic endothelial cell activity. | 2012-07-26 |
20120190613 | ECHINOCANDIN DERIVATIVES - The invention features echinocandin class compounds that have been modified to (i) have activity against one or more fungal species or genera; (ii) have increased aqueous solubility; (iii) have an increased therapeutic index; (iv) be suitable for topical administration; and/or (v) be suitable for oral administration. The echinocandin class compounds of the invention include, for example, a PEG, alkyl-PEG, aryl-PEG, alkaryl-PEG, PEG-alkyl, PEG-aryl, or PEG-alkaryl substituent. | 2012-07-26 |
20120190614 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2012-07-26 |
20120190615 | METHODS AND COMPOSITIONS FOR INDUCING WEIGHT LOSS - The present invention provides compositions and methods for inducing weight loss, preventing weight gain, and/or treating obesity-related conditions such as diabetes by inducing the production of brown adipose tissue in subjects by administering orexin or biologically active fragments thereof. | 2012-07-26 |
20120190616 | Analogues of Insulin-Like Growth Factor-1 (IGF-1) Having Amino Acid Substitution at Position 59 - The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn | 2012-07-26 |
20120190617 | NIACIN AND/OR TRIGONELLINE AS A MUSCLE STIMULANT - This invention relates to the use of niacin and/or trigonelline compounds to increase muscle weight during periods of activity or to inhibit muscle loss during periods of inactivity. | 2012-07-26 |
20120190618 | METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TRANS-BUCCAL MUCOSA TREATMENT OF POSTPRANDIAL HYPERGLYCAEMIA IN TYPE II DIABETES - The invention provides a method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. The invention also pertains to a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes. | 2012-07-26 |
20120190619 | METHODS OF IDENTIFYING ANTI-INFLAMMATORY COMPOUNDS - A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing WIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN(+) cell to signal a second effector macrophage, causing an increase in expression of the FcγRIIB receptor and in turn inhibiting a cellular-mediated inflammatory response. | 2012-07-26 |
20120190620 | METHODS TO IDENTIFY TARGETS AND MOLECULES REGULATING PURINOSOMES AND THEIR USES - The present invention discloses methods to identify targets, pathways and molecules regulating purinosomes and their uses for treating pathophysiological disorders associated with purinosomes. Disclosed are methods related to both label-free cellular assays and fluorescence imaging to confirm the regulatory roles of various targets and molecules in purinosome dynamics. Disclosed are methods to classify molecules and the uses of these molecules for different indications. Specifically, the purinosome-disrupting molecules can be used for improved prevention and treatment of cancer development. | 2012-07-26 |
20120190621 | CORNEAL ENDOTHELIAL CELL PROLIFERATION PROMOTER - The present invention aims to provide a corneal endothelium cell proliferation accelerator and a therapeutic agent for a disease relating to corneal endothelium damage, which are administered into the anterior chamber. bFGF is released in a sustained manner by forming bFGF sustained-release gelatin hydrogel particles wherein bFGF is carried on gelatin hydrogel. Therefore, the proliferation of corneal endothelium cells can be accelerated persistently by administration of a preparation containing the bFGF sustained-release gelatin hydrogel particles into the anterior chamber, and diseases relating to corneal endothelium damage can be treated. | 2012-07-26 |
20120190622 | INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR-HEAT SHOCK PROTEIN 90 BINDING INTERACTION - Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of increasing degradation of an EGFR, methods of treating cancer, and methods of sensitizing tumors to radiation therapy. | 2012-07-26 |
20120190623 | Inactivation Resistant Factor VIII - The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. The nucleic acid sequences of the present invention also encode amino acid sequences corresponding to known human FVIII sequences, wherein the APC cleavage sites, Arg336 and Ile562, are mutated. The nucleic acid sequences of the present invention further encode amino acid sequences corresponding to known human FVIII sequences, wherein the B-domain is deleted, the von Willebrand factor binding site is deleted, a thrombin cleavage site is mutated, an amino acid sequence spacer is inserted between the A2- and A3-domains. Methods of producing the FVIII proteins of the invention, nucleotide sequences encoding such proteins, pharmaceutical compositions containing the nucleotide sequences or proteins, as well as methods of treating patients suffering from hemophilia, are also provided. | 2012-07-26 |
20120190624 | PSI-EPSILON RACK PEPTIDE COMPOSITION AND METHOD FOR PROTECTION AGAINST TISSUE DAMAGE DUE TO ISCHEMIA - A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event. | 2012-07-26 |
20120190625 | NOVEL PEPTIDE AND USE THEREOF - The present invention provides a peptide comprising an amino acid sequence of SEQ ID NO: 1, a variant thereof and a pharmaceutically acceptable salt thereof. | 2012-07-26 |
20120190626 | AMYLOID BETA FIBRILLOGENESIS-INHIBITING PEPTIDE - The present invention provides a peptide which functions as a mimic peptide of an amyloid β peptide and is capable of inhibiting the fibrillogenesis of an amyloid β peptide. The present invention relates to an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (I): X | 2012-07-26 |
20120190627 | COSMETIC USE OF LACRITIN-TYPE POLYPEPTIDES - The present invention is directed to the use, in particular cosmetic use, of an effective amount of at least one lacritin-type polypeptide, of an analogue thereof or of a fragment thereof, of at least one nucleic acid sequence encoding this polypeptide, or of at least one agent that modulates the activity, the stability or the expression of this polypeptide, or its interaction with syndecan-1, as an agent useful for the care of the skin and of appendages thereof. | 2012-07-26 |
20120190628 | GENES AND POLYPEPTIDES RELATING TO HUMAN COLON CANCERS - The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease. | 2012-07-26 |
20120190629 | LIGHT-RECEIVING CHANNEL RHODOPSIN HAVING IMPROVED EXPRESSION EFFICIENCY - Disclosed is a Volvox carteri-derived light-receiving channel rhodopsin with an improved expression efficiency on a cell membrane. Specifically disclosed is a modified Volvox carteri-derived light-receiving channel rhodopsin protein. The protein is modified to contain an N-terminal region of Chlamydomonas reinhardtii-derived channel rhodopsin-1 at the N-terminal of the Volvox carteri-derived light-receiving channel rhodopsin protein, wherein the N-terminal region is involved in cell membrane-localized expression and contains no transmembrane domain of the Chlamydomonas reinhardtii-derived channel rhodopsin-1. | 2012-07-26 |
20120190630 | AMINO ACID-BASED COMPOUNDS, THEIR METHODS OF USE, AND METHODS OF SCREENING - Described herein are compounds that comprise amino acids and their pharmaceutical compositions. Methods used to administer the compounds are described. Screening methods including those for determining | 2012-07-26 |
20120190631 | MATERIALS AND METHODS RELATING TO GLYCOSYLATION - Techniques to glycosylation are described, and more particularly to the production of glycosylation structures that are resistant to enzymatic degradation, thereby modulating one or more of their biological properties or those of therapeutic moieties incorporating them, and in particular to reacting activated carbohydrate substrates containing fluorine, such as 3-fluoro sialic acid compounds, with sugar acceptors to produce covalent conjugates of the sugar acceptor and one or more of the sialic acid compounds. | 2012-07-26 |
20120190632 | ANTI-BACTERIAL INFECTION, INFLAMMATION, AND LEUKEMIA COMPOSITION AND USE THEREOF - A method of inhibiting the growth of Gram-positive bacteria comprising administering an effective amount of Tellimagrandin II, its pharmaceutically acceptable salt, enantiomer, isomer or tautomer to a subject is provided. The Gram-positive bacteria comprise methicillin-resistant | 2012-07-26 |
20120190633 | MONOPHOSPHORYLATED LIPID A DERIVATIVES - The present invention provides for monophosphorylated lipid A derivatives and carbohydrate derivatives that are useful as agents in the treatment of diseases and conditions, including cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I-IV. In addition, methods for the treatment of cancers are provided. | 2012-07-26 |
20120190634 | LIPOTEICHOIC ACID-DERIVED GLYCOLIPIDS, AND COMPOSITIONS COMPRISING SAME - A lipoteichoic acid (LTA)-derived glycolipid, and a pharmaceutical, food or cosmetic composition and a vaccine adjuvant including the same are provided. The LTA-derived glycolipid can inhibit the production of inflammatory cytokines and thus have anti-inflammatory effects. Therefore, the pharmaceutical, food or cosmetic compositions including the LTA-derived glycolipid can be used to prevent and treat inflammatory diseases, and the LTA-derived glycolipid can be also used as the vaccine adjuvant. | 2012-07-26 |
20120190635 | SELECTIVE OXIDATION OF C-H BONDS OF MODIFIED SUBSTRATES BY P450 MONOOXYGENASE - The present invention provides regio- and stereoselective oxidation of unactivated C—H bonds using an engineered mutant cytochrome P450 monooxygenase and an engineered substrate. | 2012-07-26 |
20120190637 | COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS - Therapeutics which employ a combination of an antiviral agent and an EP4 receptor agonist for the treatment of human respiratory diseases associated with viral infections are described. Viral infections may include an influenza A virus, for example H1N1, H3N2 and H5N1, and mutations thereof, and/or a coronavirus, for example a virus that causes severe acute respiratory syndrome, “SARS”. | 2012-07-26 |
20120190638 | METHODS OF TREATING HEMATOLOGIC CANCERS - This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described. | 2012-07-26 |
20120190639 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS - The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer. | 2012-07-26 |
20120190640 | CYANOCOBALAMIN LOW VISCOSITY AQUEOUS FORMULATIONS FOR INTRANASAL DELIVERY - A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering, intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.1 comprising intranasally administering an aqueous solution of a cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 7% relative to an intramuscular injection of a cyanocobalamin. | 2012-07-26 |
20120190641 | Use of Non-Digestible Oligosaccharides - Use of a non-digestible oligosaccharide or salt thereof for producing an anti proliferative effect in a subject wherein the non-digestible oligosaccharide is of formulae (i) [A]-[B] | 2012-07-26 |
20120190642 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. | 2012-07-26 |
20120190643 | CARBOHYDRATE COMPOSITION FOR FLAT GLUCOSE RESPONSE - A low-glycemic available carbohydrate composition of the invention contains the following components:
| 2012-07-26 |
20120190644 | VISCOELASTIC GELS AS NOVEL FILLERS - Biomaterials obtainable by mixing
| 2012-07-26 |
20120190645 | Organic compounds - The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery. | 2012-07-26 |
20120190646 | Compositions Comprising Thalidomide and Artemisinin for the Treatment of Cancer - The present invention relates to pharmaceutical compositions for the treatment of cancer and especially for the treatment of hematological malignancies such as multiple myeloma. Specifically, the present invention relates to pharmaceutical composition for the treatment of cancer comprising: thalidomide, or a derivative thereof, or salts or solvates thereof; one or more artemisinin compounds, or salts or solvates thereof; and one or more pharmaceutically acceptable carriers and/or excipients. | 2012-07-26 |
20120190647 | NOVEL ORAL FORMS OF A PHOSPHONIC ACID DERIVATIVE - Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using them. | 2012-07-26 |
20120190648 | FLUORINATED CYCLOPROPANE ANALOGS OF GLUTAMIC ACID - The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a mixture in all proportions of stereoisomers thereof, in particular a mixture of enantiomers, such as a racemic mixture, wherein R represents a (C | 2012-07-26 |
20120190649 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS - Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors. | 2012-07-26 |
20120190650 | Inhibitors of Autotaxin - Stabilized benzyl phosphonic acid and naphthyl phosphonic acid analog compounds are effective in inhibiting the activity of autotaxin. | 2012-07-26 |
20120190651 | ANTI-INFLAMMATORY COMPOUNDS - This invention relates to novel compounds obtained by fermentation of Myxobacteria strain (PM0670013/MTCC 5570). The present invention further relates to the processes for the production of the novel anti-inflammatory compounds, to the culture no. PM0670013 (MTCC 5570), and to pharmaceutical compositions containing compounds of the present invention as an active ingredient and its use in medicines for the treatment of inflammatory diseases or disorders mediated by proinflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-α) and/or interleukins such as IL-6, having anti-inflammatory activity The invention also includes all stereoisomeric forms of compounds of the present invention. | 2012-07-26 |
20120190652 | DIAGNOSTIC AGENT FOR PARKINSON'S DISEASE - The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD in the pre-symptomatic phase of the disease or to distinguishing PD from another neurological disorder. The method of the invention comprises measuring the amount of soluble α-synuclein oligomers in a cerebrospinal fluid sample taken from an individual. The method optionally also comprises measuring the total amount of α-synuclein in the CSF sample, calculating the ratio of the amount of α-synuclein oligomers to the total amount of α-synuclein, and thereby determining whether or not the individual has PD. The method of the invention can be used in clinical trials to measure the effect of drugs in both PD animal models and human PD patients. | 2012-07-26 |
20120190653 | THERAPEUTIC EYE DROP COMPRISING DOXYCYCLINE AND A STABILIZER - The present invention provides stable aqueous doxycycline aqueous solutions suitable for pharmaceutical, especially ophthalmic, use. The doxycycline aqueous solutions have a pH ranging from 4.5-8, and contain an antioxidant and a stabilizer such as caffeine, creatine or mixtures thereof. The solutions have improved lifetimes and can be used topically. | 2012-07-26 |
20120190654 | NOVEL BICYCLIC UREA COMPOUNDS - The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 2012-07-26 |
20120190655 | Intravenous Formulation with Water-Soluble CoCrystals of Acetylsalicylic Acid and Theanine - An aspirin-theanine cocrystal composition including a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer combined with the quantity of acetylsalicylic acid in a mixture. The theanine enantiomer may be L-theanine, D-theanine, or DL-theanine | 2012-07-26 |
20120190656 | METHODS FOR SELECTING THERAPIES TO IMPROVE HDL CHOLESTEROL AND TRIGLYCERIDE LEVELS - Disclosed herein are diagnostic methods for determining whether subjects will be responsive to vitamin D therapy. The methods involve the detection of one or more single nucleotide polymorphisms in a test sample, in combination with other clinical factors. The tests are suitable for diagnosing and determining a treatment regime for patients having or suspected of having a cardiovascular disease, including hyperlipidemia or hypertriglyceridemia. | 2012-07-26 |
20120190657 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - This invention provides compounds of formula I: | 2012-07-26 |
20120190658 | Method And Composition For The Treatment Of Adverse Skin Conditions - A multi-component medicament composition for the treatment of adverse skin conditions such as eczema or psoriasis comprises a combination of a steroid and silicone. | 2012-07-26 |
20120190659 | ANGIOGENESIS INHIBITORS - Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis: | 2012-07-26 |
20120190660 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIENE-11-ETHYNYLPHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-ethynylphenyl derivatives of the formula I, in which R | 2012-07-26 |
20120190661 | ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION - The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions. | 2012-07-26 |
20120190662 | PHARMACEUTICAL PROPYLENE GLYCOL SOLVATE COMPOSITIONS - The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs. | 2012-07-26 |
20120190663 | USE OF FREE DNA AS AN EARLY PREDICTOR OF SEVERITY IN ACUTE PANCREATITIS - This invention provides methods of determining the risk of AP development in an individual, as well as the diagnosis, prognosis, and treatment of acute pancreatitis (AP) in an individual, by determining the presence or absence of significantly high levels of free serum DNA in the subject relative to levels in a healthy individual. In other embodiments, the invention further provides methods of determining the risk of severe AP development, prognosis, diagnosis, and treatment of a severe form of acute pancreatitis based upon the presence of significantly high levels of free serum DNA in the subject relative to an individual who has and maintains a mild form of acute pancreatitis. | 2012-07-26 |
20120190664 | PROCESS FOR THE PREPARATION OF ANTIBIOTIC COMPOUNDS - The present invention relates to a process for the preparation of carbapenem antibiotic compounds, which are useful for intravenous and intramuscular administration. | 2012-07-26 |
20120190665 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS - A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R | 2012-07-26 |
20120190666 | Heteroaryl Compounds as PIKK Inhibitors - The present invention provides compounds that are PIKK inhibitors, more specifically, mTOR and/or PI3Kα kinase inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of kinases, specifically PI3 kinases, more specifically, mTOR and/or PI3Kα, such as cancer. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. | 2012-07-26 |
20120190667 | METHOD OF MAKING SOLID DISPERSIONS OF HIGHLY CRYSTALLINE THERAPEUTIC COMPOUNDS - A process for preparing solid dispersions of highly crystalline compounds. The highly crystalline or thermally labile therapeutic compounds are processed in an extruder in combination with a solubilizing agent and optionally a plasticizer. The resulting extrudate features the therapeutic compound in an amorphous state. Particularly useful as the solubilizing agents are surfactants such as poloxamers. | 2012-07-26 |
20120190668 | ENHANCEMENT OF CELLULAR TRANSPLANTATION USING SMALL MOLEUCLE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY - The present invention provides methods for enhancing cellular transplantation by exposing cells in vitro or ex vivo, or a recipient of cells, to a small molecule hepatocyte growth factor/scatter factor mimetic. Exemplary compounds are described. | 2012-07-26 |
20120190669 | OXINDOLE COMPOUNDS - The invention provides compounds that inhibit PIM kinases and Flt3 kinase, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation. | 2012-07-26 |
20120190670 | Transnasal Anticonvulsive Pharmaceutical Composition Comprising Poorly Soluble Anticonvulsant - There is provided a transnasal anticonvulsive pharmaceutical composition including a poorly soluble anti-convulsant. The anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether and fatty acid ester, wherein the fatty acid ester is selected from the group consisting of caprylocaproyl polyoxylglyceride, isopropyl palmitate, oleoyl polyoxylglyceride, sorbitan monolaurate 20, methyl laurate, ethyl laurate, and polysorbate 20. Also, the anticonvulsive pharmaceutical composition comprising a poorly soluble anticonvulsant as an active component, which is transnasally spray-administered, comprises diethylene glycol monoethyl ether, fatty acid ester, methylpyrrolidone, water and alcohol. Therefore, the transnasal anticonvulsive pharmaceutical composition may be useful to highly enhance the bioavailability of the poorly soluble anticonvulsant. Also, the transnasal anticonvulsive pharmaceutical composition may be useful to allow the poorly soluble anticonvulsant to show the improved viscosity and/or enhanced solubility in order to effectively deliver the poorly soluble anticonvulsant at a therapeutic dose. | 2012-07-26 |
20120190671 | Controlled-Release CNS Modulating Compositions and Methods for the Treatment of Otic Disorders - Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s). | 2012-07-26 |
20120190672 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES - The present invention relates to a fused aminodihydrothiazine derivative of formula (I): | 2012-07-26 |
20120190673 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES - The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R′, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase. | 2012-07-26 |
20120190674 | SULFONAMIDES AS TRPM8 MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 2012-07-26 |
20120190675 | Azaspirohexanones - The present invention relates to compounds defined by formula I | 2012-07-26 |
20120190676 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS - The present invention provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR. The invention also provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR and modulators of the unfolded protein response. | 2012-07-26 |
20120190677 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES - The present invention relates to a compound of formula (I) | 2012-07-26 |
20120190678 | SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS - The present invention relates to substituted pyrazolo[4,3-h]quinazoline compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular PIM kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them. | 2012-07-26 |
20120190679 | Novel Protein Kinase B Inhibitors - 060 - The invention relates to a novel group of compounds of Formula (I) or salts thereof: | 2012-07-26 |
20120190680 | Heteroaryl Amide Analogues - Compounds, pharmaceutical compositions, and methods of use are disclosed for heteroaryl amide analogues of formula Ia and/or Ib: | 2012-07-26 |
20120190681 | PICOLINAMIDE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 2012-07-26 |
20120190682 | MODULATORS FOR AMYLOID BETA - The invention relates to compounds of formula | 2012-07-26 |
20120190683 | INSECTICIDAL SUBSTITUTED AZINYL DERIVATIVES - N-Azinyl-N′-aryl ureas and thioureas derivatives are effective at controlling insects. | 2012-07-26 |
20120190684 | INSECTICIDAL SUBSTITUTED AZINYL DERIVATIVES - N-Azinyl-N′-aryl ureas and thioureas derivatives are effective at controlling insects. | 2012-07-26 |
20120190685 | NOVEL PHENYLIMIDAZOLE DERIVATIVE AS PDE10A ENZYME INHIBITOR - This invention provides the compound 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]thazolo[1,5-a]pyrazine and pharmaceutically acceptable acid addition salts thereof. | 2012-07-26 |
20120190686 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME - The present invention provides bicyclo[3.2.1]octyl amide derivatives of formula (I): | 2012-07-26 |
20120190687 | Pyrazinylpyrazoles - Pyrazin-2-ylpyrazoles are described, as is the use thereof as insecticides and/or parasiticides. | 2012-07-26 |
20120190688 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2012-07-26 |
20120190689 | PIPERAZINYL 3-AMINOPYRROLIDINE DERIVATIVES AS A CCR2 ANTAGONIST - The present invention relates to compounds of chemical formula 1 and having CCR2 (chemokine receptor 2) antagonistic effects, and salts or isomers thereof. These compounds are very useful for treating, preventing, or relieving rheumatoid arthritis, arteriosclerosis, multiple sclerosis, asthma, and various diseases related to CCR2. | 2012-07-26 |
20120190690 | ELTOPRAZINE FOR THE TREATMENT OF WEIGHT DISORDERS - The present invention relates to the treatment of an individual afflicted with a weight disorder, particularly obesity, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof. | 2012-07-26 |
20120190691 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES - The present invention relates to pharmaceutical composition comprising a CRTH2 antagonist and at least one histamine receptor antagonist, medicaments containing said pharmaceutical compositions, and the use of said pharmaceutical compositions for treating respiratory and inflammatory diseases and conditions. | 2012-07-26 |